Mohammed Mustafa Nayeem, MD1, Mena Tawfik, MD2, Rajiv Singh, MD2, Uday Patel, DO2, Aleena Sammar, MD2, Nida Firdous, MD2, Jatinbhai Patel, MBBS2 1Parkview Medical Center, Peublo, CO; 2Parkview Medical Center, Pueblo, CO
Introduction: Bezlotoxumab is a monoclonal antibody shown to reduce the recurrence of CDI . The 2021 IDSA/SHEA focused update of guidelines for management C Diff recommends use of Bezlotoxumab as a co-intervention, along with standard of care antibiotics, in patients with recurrent CDI within 6 months. Furthermore, use of Bezlotoxumab is also suggested in patients with primary CDI with high risk of recurrence - Age >65, immunocompromised host and severe CDI on presentation. In this retrospective analysis, we aim to assess the rate of utilization of Bezlotoxumab and adherence to IDSA/SHEA guidelines in a community hospital.
Methods: EMR data abstraction tolls were utilized to identify patients diagnosed with CDI and admitted to the hospital between June 1, 2022, and May 31st, 2023
Chart review was performed to determine eligibility for Bezlotoxumab infusion at an outpatient infusion center. Since exacerbation of congestive heart failure is a potential side effect of Bezlotoxumab, patients with heart failure were excluded from the analysis.
Results: Data from hospitalizations of patients with C diff colitis (June2022→June2023- N 81 ) were collected.
We further excluded patients who either left Against medical advice (3) or expired during the same hospital visit (2) and patients with history of heart failure ( 9) .
Out of the remaining 67 patients identified as having CDI, 37 (55%) patients were considered appropriate candidates for Bezlotuxamab infusion for prevention of CDI. However, Bezlotoxumab infusion was recommended in only 3 patients (8%).
Discussion: Two randomized controlled trials have shown reduced CID recurrence after initial cure at 12 weeks with use of Bezlotoxumab. However, Bezlotoxumab remains underutilized for prevention of CDI. Increase in awareness about this intervention may reduce CDI recurrence.
Disclosures:
Mohammed Mustafa Nayeem indicated no relevant financial relationships.
Mena Tawfik indicated no relevant financial relationships.
Rajiv Singh indicated no relevant financial relationships.
Uday Patel indicated no relevant financial relationships.
Aleena Sammar indicated no relevant financial relationships.
Nida Firdous indicated no relevant financial relationships.
Jatinbhai Patel indicated no relevant financial relationships.
Mohammed Mustafa Nayeem, MD1, Mena Tawfik, MD2, Rajiv Singh, MD2, Uday Patel, DO2, Aleena Sammar, MD2, Nida Firdous, MD2, Jatinbhai Patel, MBBS2. P1214 - Rate of Utilization of Bezlotoxumab for Prevention of Clostridioides difficile Infection Recurrence in a Community Hospital, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.
